Diagnostics Technology Development Opportunities / The Major Market Opportunities in RAM

company logo

Dublin, July 27, 2022 (GLOBE NEWSWIRE) — The “Antimicrobial Resistance Diagnostics Markets, Strategies, and Trends by Pathogen and Technology, with Executive Guides and Personalization” report has been added to from ResearchAndMarkets.com offer.

Make investment decisions and valuations with confidence using the latest data and 5-year forecasts

Diagnostics are leading the charge to reduce the threat posed by antimicrobial resistance. Will these technologies solve the problem before new antibiotics arrive? New diagnostic technologies, beyond genetic sequencing, are being developed to capture this growing market.

The editor has reviewed the image of the technology, giving you a plain language understanding of the different ways pathogens and infections can be diagnosed. The report identified the top 6 major pathogen opportunities in this space and developed market forecasts. We present more than 30 companies, large and small, working in this field.

Main topics covered:

1 Market guides
1.1 Antimicrobial Resistance – Strategic Situation Analysis
1.2 Guide for executives and business development staff
1.3 Management Advisor and Investment Advisor Guide

2 Introduction and market definition
2.1 The threat and opportunity of antimicrobial resistance
2.2 Defining the opportunity
2.2.1 Revenue Market Size
2.3 Methods and sources
2.3.1 Methodology
2.3.2 Origin
2.3.3 Authors
2.4 US Antibiotics Markets – Perspective
2.4.1 Ambulatory Use of Antibiotics in the United States
2.4.2 Pharmaceutical expenditure in the United States

3 Snapshot of a dynamic market
3.1 Market Players – Roles and Impacts
3.1.1 Drug Manufacturers – Larger/Pharmaceutical
3.1.2 Drug Manufacturers – Generics
3.1.3 Contract research and manufacturing
3.1.4 In Vitro Diagnostics Industry
3.1.5 Drug Marketing Companies
3.1.6 Biotechnology companies
3.1.7 Regulatory Bodies
3.2 Understanding antimicrobial resistance
3.2.1 What is Antimicrobial Resistance (AMR)
3.2.2 Bacteria and other microbes
3.2.3 The history of antibiotics
3.2.4 The role of livestock
3.2.5 Implications of horizontal transfer
3.2.6 The threat of RAM
3.3 The Changing Path to New Antibiotics and Technologies
3.4 The key role of diagnostics in RAM

4 The RAM market opportunity
4.1 Major Market Opportunities in RAM
4.1.1 Streptococcus pneumoniae (DRSP)
4.1.2 Campylobacter (DRC)
4.1.3 Clostridium difficile (CD)
4.1.4 Staphylococcus aureus (MRSA)
4.1.5 Neisseria gonorrhoeae (DRNG)
4.1.6 Salmonella (DRNTS)87
4.2 Diagnostic Technology Development Opportunities
4.2.1 What’s wrong with microbiology
4.2.2 The functional battlefield of infectious disease diagnostics
4.2.3 Multiplex vs. POC/Rapid
4.2.4 The miracle of genetics
4.2.5 From multiple pathogens to all pathogens – The next generation
4.2.6 Gene sequence diagnosis WITHOUT sequencing
4.2.7 Resistance Markers.
4.2.8 What happens to the microbiology laboratory?

5 Antibiotic Resistance Diagnostics Recent Developments
5.1 Recent developments in antibiotic resistance
5.1.1 Significance of these developments
5.1.2 How to use this section
5.2 T2 Biosystems Exercises BARDA Option
5.3 OpGen to Accelerate Use of Acuitas AMR Gene Panel
5.4 BD partners with Pfizer, welcome to study AMR Dx
5.5 Sepsis test developers are accelerating their plans
5.6 OpGen Receives FDA Clearance for AMR Panel
5.7 Visby Medical – Rapid adoption of portable PCR test for STIs
5.8 MicroGenDx, OrthoKey Clinic and OrthoKey Surgery
5.9 BioMérieux receives CE marking for the Vitek clinical microbiology system
5.10 Hologic to Acquire Mobidiag
5.11 Campylobacter strains exchange genes
5.12 Disinfection Spreads Antimicrobial Resistance
5.13 Molzym, Fraunhofer Develop sepsis fast Dx
5.14 Illumina, IDbyDNA Build NGS-Based Respiratory Panel
5.15 Accelerate Diagnostics expands AMR testing
5.16 Rapid diagnosis linked to optimal antibiotic therapy
5.17 Visby Medical wins AMR diagnostic competition
5.18 DNAe Technology SARS-CoV-2 Sequences
5.19 Foodborne bacterial infections are getting harder to treat
5.20 Dust shares antibiotic resistance genes
5.21 Report predicts drug resistance will likely kill 400,000 people
5.22 New method for testing resistance to infection.
5.23 Qiagen launches AMR database
5.24 Antibiotic resistance test for gonorrhea gets FDA breakthrough
5.25 Qiagen, Ares Genetics Ink Licensing Pact for AMR Bioinformatics

6 key AMR diagnostic companies
6.1 Diagnosis 1928
6.2 Abacus Diagnostica
6.3 Abbott Laboratories
6.4 Accelerate diagnostics
6.5 ADT Biotech
6.6 Beckman Coulter Diagnosis
6.7 Becton, Dickinson and company
6.8 Binx Health
6.9 bioMérieux Diagnostics
6.10 Bio-Rad Laboratories, Inc.
6.11 Cepheid (Danaher)
6.12 Curetis AG/Curetis GmbH
6.13 Day Zero Diagnosis
6.14 Enzo Biochemistry
6.15 Scientific Eurofins
6.16 Genome Fusion
6.17 GeneFluidics
6.18 Great Basin Society
6.19 Hological
6.20 Hutman Diagnosis
6.21 Inflammatix
6.22 Linear diagnostics
6.23 Lumos Diagnosis
6.24 Millipore Sigma
6.25 OpGen
6.26 Orthoclinical diagnostics
6.27 Perkin Elmer
6.28 Qiagen
6.29 Roche Molecular Diagnostics
6.30 SeLux Diagnosis
6.31 Sensory biosensing
6.32 Siemens Healthineers
6.33 Systemex
6.34 Thermo Fisher Scientific Inc.
6.35 Visby Medical

7 The Global Antimicrobial Resistance Diagnostics Market
7.1 Global Market Overview by Country
7.2 Global Market by Technology – Overview

8 Global Antibiotic Resistance Diagnostics Markets – By Pathogen
8.1 Drug-resistant Streptococcus pneumoniae – DRSP
8.2 Drug resistant Campylobacter – DRC
8.3 Clostridium difficile – CD
8.4 Methicillin-resistant Staphylococcus aureus – MRSA
8.5 Drug resistant Neisseria gonorrhoeae – DRNG
8.6 Drug Resistant Salmonella – DRNTS

9 Global Antibiotic Resistance Diagnostics Markets – By Technology
9.1 Microbiological culture
9.2 Immunoassay
9.3 PCR
9.4 NGS
9.5 Mass spectrometry – MS
9.6 Rapid and Point of Service – Rapid/POC

10 Vision of the future of RAM diagnostics

For more information on this report, visit https://www.researchandmarkets.com/r/zencu1

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager [email protected] For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900


Source link

Comments are closed.